ESGMYC conceived a thematic section on multidrug and extensively drug-resistant tuberculosis published in CMI, 2017, Volume 23

This section included the following reviews: Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis by Dheda et al., Multidrug-resistant tuberculosis and migration to Europe by Hargreaves et al., Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases by Fox et al., Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives by Schön et al., Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testing by Walker et al.


Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. Andre et al., Int J Tuberc Lung Dis. 2016; 20(8):999-1003

The use of new diagnostic tests has increased dramatically in the laboratories of developing countries and in decentralised point-of-care facilities. Self-contained molecular diagnostic devices have been successfully deployed to detect tuberculosis (TB) in very basic clinical facilities. However, the introduction of an improved TB diagnostic tool is not sufficient to assure improved outcomes for patients, as the details of implementation within existing health delivery systems have a critical influence on impact. Diagnostic e-health solutions have the potential to help maximise patient and public health impact following the introduction of a particular technology. In this opinion paper, authors discussed lessons learned from the global scale-up of the first generation of easy-to-connect diagnostic tools and the pathway to tapping the potential of connectivity in the field of TB diagnostics.